Ricarda Tomlin
she/her/hers
Research Support Manager 4Cards
About
Research
Publications
2022
Major Depressive Disorder in an International Multisite Wilson Disease Registry
Camarata M, Ala A, Coskun A, Deng Y, Embel V, Gonzalez-Peralta R, Maciejewski K, Patel A, Rubman S, To U, Tomlin R, Schilsky M, Zimbrean P. Major Depressive Disorder in an International Multisite Wilson Disease Registry. Journal Of The Academy Of Consultation-Liaison Psychiatry 2022, 64: 106-117. PMID: 36521682, DOI: 10.1016/j.jaclp.2022.12.001.Peer-Reviewed Original ResearchConceptsMajor depressive disorderWilson's diseaseDepressive disorderLifetime major depressive disorderMental health QOLPhysical health QoLMajor depressive episodeMental health qualityStructured psychiatric evaluationSignificant differencesCross-sectional reportsLiver testsLiver diseaseNeurological assessmentLife scoresClinical correlatesDepressive episodePsychiatric symptomsPsychiatric evaluationDisease RegistrySevere anxietyLaboratory testsLifetime historySignificant associationPatients
2021
National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR, Piquant D, Link K, Hemmersbach-Miller M, Pearson T, Turgeon N, Lyon G, Kitchens W, Huckaby J, Lasseter A, Elbein R, Roberson A, Ferry E, Klock E, Cochran W, Morrison M, Rasmussen S, Bollinger J, Sugarman J, Smith A, Thomas M, Coakley M, Timpone J, Stucke A, Haydel B, Dieter R, Klein E, Neumann H, Gallon L, Goudy L, Callegari M, Marrazzo I, Jackson T, Pruett T, Farnsworth M, Locke J, Mompoint-Williams D, Basinger K, Mekeel K, Nguyen P, Kwan J, Srisengfa T, Chin-Hong P, Rogers R, Simkins J, Munoz C, Dunn T, Sawinski D, Silveira F, Hughes K, Pakstis D, Nagy J, Baldecchi M, Muthukumar T, Eddie M, Robb K, Salsgiver E, Witting B, Azar M, Villanueva M, Formica R, Tomlin R. National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases 2021, 74: 2010-2019. PMID: 34453519, PMCID: PMC9187316, DOI: 10.1093/cid/ciab743.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistance mutationsHIV-positive donorsHIV drug resistance mutationsViral loadMedian CD4 T-cell countCD4 T-cell percentagesHIV Organ Policy Equity (HOPE) ActCD4 T-cell countNonnucleoside reverse transcriptase inhibitorIntegrase strand transfer inhibitorsDonor-derived infectionInhibitor-based regimensT cell percentageT-cell countsHepatitis C viremiaHIV viral loadCD4 T cellsDeceased organ donorsReverse transcriptase inhibitorFalse-positive test resultsStrand transfer inhibitorsC viremiaVirologic characteristicsClinical characteristicsThe Effect of Mental Health, Neurological Disease, and Liver Disease on Quality of Life in Patients With Wilson Disease
Camarata MA, Ala A, Coskun AK, Deng Y, Gonzalez-Peralta R, Maciejewski KR, Patel A, Rubman S, To U, Tomlin R, Schilsky ML, Zimbrean PC. The Effect of Mental Health, Neurological Disease, and Liver Disease on Quality of Life in Patients With Wilson Disease. Journal Of The Academy Of Consultation-Liaison Psychiatry 2021, 62: 528-537. PMID: 34044196, PMCID: PMC11165927, DOI: 10.1016/j.jaclp.2021.04.004.Peer-Reviewed Original ResearchConceptsRating Scale scoresP-QOL scoresP-QOLNeurological diseasesWilson's diseaseMental healthOverall QoLUnified Wilson's Disease Rating Scale scoreScale scoreEnd-stage liver disease (MELD) scoreDisease severityStage liver disease scoreDegree of liverNeurological disease severityLiver Disease scoreLiver disease severityMajor depressive disorderQuality of lifeMental health issuesChild-PughCirrhosis severityLiver diseaseNeurological assessmentPatients' qualityChronic disorders
2020
P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease
Camarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Coskun A, Patel A, Wadhwa A, Apdik T, Tomlin R, Deng Y, Gonzalez-Peralta R, Schilsky M. P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease. Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.23.Peer-Reviewed Original ResearchMental health issuesWilson's diseaseHealth issuesSeverity of liverMental health QOLPhysical health QoLReview of imagingP-QOL scoresQuality of lifeFIB4 scoreAdult patientsRegistry studyNeurological assessmentPhysical health issuesChronic diseasesOutcome measuresPatientsNeurological diseasesWD patientsQoLAssess qualityDiseaseCirrhosisSignificant differencesScores257 Bipolar disorder in patients with Wilson disease
Zimbrean P, Rubman S, Maciejewski K, Coskun, Nalamada K, Camarata M, Tomlin R, Patel A, To U, Ala A, Gonzalez-Peralta R, Deng Y, Schilsky M. 257 Bipolar disorder in patients with Wilson disease. Journal Of Psychosomatic Research 2020, 133: 110055. DOI: 10.1016/j.jpsychores.2020.110055.Peer-Reviewed Original Research
2019
Major depressive disorder in patients with Wilson disease
Zimbrean P, Gold S, Nalamada K, Camarata M, Tomlin R, Patel A, Vives-Rodrigues A, Ekong U, Bramford N, Valentino P, To U, Deng Y, Song X, Ala A, Schilsky M. Major depressive disorder in patients with Wilson disease. Journal Of Psychosomatic Research 2019, 121: 148. DOI: 10.1016/j.jpsychores.2019.03.145.Peer-Reviewed Original Research
2018
Clinical Research Participation
Tomlin R. Clinical Research Participation. Clinical Gastroenterology 2018, 213-222. DOI: 10.1007/978-3-319-91527-2_13.ChaptersPrimary care physiciansClinical researchWillingness of patientsClinical research participationPrevention of diseaseCare physiciansInformed consent processStudy participationRare diseasePatientsStudy participantsWilson's diseaseDiseaseConsent processResearch participationParticipantsPhysiciansDiagnosisPreventionRace, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant
McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, Kulkarni S, Esnaola G, Shults J, Thiessen C, Reese PP. Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation 2018, 102: e163-e170. PMID: 29346260, DOI: 10.1097/tp.0000000000002099.Peer-Reviewed Original ResearchConceptsHepatitis C virusHCV cure ratesCure rateC virusUninfected kidneyEnd-stage renal disease patientsHCV-negative patientsPrior transplant recipientsRenal disease patientsHigh cure ratesEffective antiviral treatmentKidney recipientsTransplant recipientsKidney transplantMost patientsOlder patientsAntiviral treatmentWhite patientsDeceased donorsAllograft qualityFuture trialsBlack raceDisease patientsPatient acceptanceYoung donors
2016
Parathyroidectomy prior to kidney transplant decreases graft failure
Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, Kulkarni S. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery 2016, 161: 44-50. PMID: 27863776, DOI: 10.1016/j.surg.2016.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesConfidence IntervalsDatabases, FactualFemaleGraft RejectionGraft SurvivalHumansHyperparathyroidismKidney Failure, ChronicKidney TransplantationMaleMiddle AgedOdds RatioParathyroid HormoneParathyroidectomyPreoperative CareRetrospective StudiesRisk AssessmentTreatment OutcomeConceptsYear post-kidney transplantationPost-kidney transplantationDelayed graft functionGraft failureKidney transplantationGraft functionParathyroid hormoneUremic hyperparathyroidismKidney diseaseFirst year post-kidney transplantationSerum parathyroid hormone levelsCurrent Kidney DiseaseGlobal Outcomes (KDIGO) guidelinesParathyroid hormone levelsSerum parathyroid hormoneAdult patientsKidney transplantOutcomes guidelinesRetrospective reviewSingle institutionCurrent guidelinesHormone levelsSurvival 1ParathyroidectomyTransplantationEculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change